465 related articles for article (PubMed ID: 30568030)
21. Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction.
Rouhani SJ; Eccles JD; Riccardi P; Peske JD; Tewalt EF; Cohen JN; Liblau R; Mäkinen T; Engelhard VH
Nat Commun; 2015 Apr; 6():6771. PubMed ID: 25857745
[TBL] [Abstract][Full Text] [Related]
22. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
Rodig SJ; Gusenleitner D; Jackson DG; Gjini E; Giobbie-Hurder A; Jin C; Chang H; Lovitch SB; Horak C; Weber JS; Weirather JL; Wolchok JD; Postow MA; Pavlick AC; Chesney J; Hodi FS
Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021886
[TBL] [Abstract][Full Text] [Related]
23. Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses.
Furtado R; Chorro L; Zimmerman N; Guillen E; Spaulding E; Chin SS; Daily JP; Lauvau G
Front Immunol; 2020; 11():576743. PubMed ID: 33519801
[TBL] [Abstract][Full Text] [Related]
24. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II.
Liang B; Workman C; Lee J; Chew C; Dale BM; Colonna L; Flores M; Li N; Schweighoffer E; Greenberg S; Tybulewicz V; Vignali D; Clynes R
J Immunol; 2008 May; 180(9):5916-26. PubMed ID: 18424711
[TBL] [Abstract][Full Text] [Related]
25. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis.
Hemon P; Jean-Louis F; Ramgolam K; Brignone C; Viguier M; Bachelez H; Triebel F; Charron D; Aoudjit F; Al-Daccak R; Michel L
J Immunol; 2011 May; 186(9):5173-83. PubMed ID: 21441454
[TBL] [Abstract][Full Text] [Related]
26. Bovine Immunoinhibitory Receptors Contribute to Suppression of Mycobacterium avium subsp. paratuberculosis-Specific T-Cell Responses.
Okagawa T; Konnai S; Nishimori A; Ikebuchi R; Mizorogi S; Nagata R; Kawaji S; Tanaka S; Kagawa Y; Murata S; Mori Y; Ohashi K
Infect Immun; 2016 Jan; 84(1):77-89. PubMed ID: 26483406
[TBL] [Abstract][Full Text] [Related]
27. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
28. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
29. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
Frey AB; Cestari S
Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
[TBL] [Abstract][Full Text] [Related]
30. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
31. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
33. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
34. PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity.
Koller P; Baran N; Harutyunyan K; Cavazos A; Mallampati S; Chin RL; Jiang Z; Sun X; Lee HH; Hsu JL; Williams P; Huang X; Curran MA; Hung MC; Konopleva M
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793852
[TBL] [Abstract][Full Text] [Related]
35. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
Kumar A; Chamoto K; Chowdhury PS; Honjo T
Elife; 2020 Mar; 9():. PubMed ID: 32122466
[TBL] [Abstract][Full Text] [Related]
36. T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.
Demeure CE; Wolfers J; Martin-Garcia N; Gaulard P; Triebel F
Eur J Cancer; 2001 Sep; 37(13):1709-18. PubMed ID: 11527700
[TBL] [Abstract][Full Text] [Related]
37. Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restores the Function of Antiviral Tissue-Resident CD8
Roy S; Coulon PG; Prakash S; Srivastava R; Geertsema R; Dhanushkodi N; Lam C; Nguyen V; Gorospe E; Nguyen AM; Salazar S; Alomari NI; Warsi WR; BenMohamed L
J Virol; 2019 Sep; 93(18):. PubMed ID: 31217250
[TBL] [Abstract][Full Text] [Related]
38. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.
Hillman GG; Kallinteris NL; Lu X; Wang Y; Wright JL; Li Y; Wu S; Forman JD; Gulfo JV; Humphreys RE; Xu M
Cancer Treat Rev; 2004 May; 30(3):281-90. PubMed ID: 15059651
[TBL] [Abstract][Full Text] [Related]
39. Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.
Axelrod ML; Cook RS; Johnson DB; Balko JM
Clin Cancer Res; 2019 Apr; 25(8):2392-2402. PubMed ID: 30463850
[TBL] [Abstract][Full Text] [Related]
40. Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
de Goeje PL; Klaver Y; Kaijen-Lambers MEH; Langerak AW; Vroman H; Kunert A; Lamers CHJ; Aerts JGJV; Debets R; Hendriks RW
Front Immunol; 2018; 9():2034. PubMed ID: 30245692
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
